Oncolytic Virus Therapies Market Outlook 2025-2033: Growth, Trends, and Opportunities

Oncolytic Virus Therapies Market Overview
The Oncolytic Virus Therapies Market is set to witness unprecedented growth in the coming years. Valued at USD 270.28 Million in 2024, it is expected to reach USD 2.21 Billion by 2033, growing at a robust CAGR of 26.30% from 2025 to 2033. This surge is fueled by the rising burden of cancer worldwide and the increasing demand for gene-based therapies and innovative research methods.

📥 Download Free Sample

Key Market Drivers
Rising Incidence of Cancer: Cancer remains a leading cause of death globally. According to the WHO, 10 million deaths were attributed to cancer in 2020, with projections estimating 18.3 million new cases and 44.2 million people living with cancer by 2021. Gene therapies, offering high selectivity and targeted treatment, are rapidly gaining traction, driving the adoption of oncolytic virus therapies.

Increasing Research Funding: The National Cancer Institute (NCI) supports cancer prevention, diagnosis, and treatment through grants like SBIR & STTR and translational research grants. This financial backing accelerates research and clinical trials, propelling innovation in oncolytic virus therapies.

High Market Potential through Drug Approvals: The FDA anticipates approving 10-20 gene therapies annually by 2025, reflecting a strong pipeline of investigational new drugs and signaling promising opportunities for market expansion.

Market Challenges
High Cost of Therapy: Personalized therapies maintain high costs due to individualized production processes. Despite their therapeutic potential, affordability and reimbursement remain significant barriers to widespread adoption.

Regional Insights
North America dominates the market, capturing 44.1% of the global share in 2024, driven by advanced healthcare infrastructure, the prevalence of hematologic malignancies, and partial reimbursement coverage. The region is expected to maintain a CAGR of 26.2%.

Asia-Pacific emerges as the fastest-growing market with a CAGR of 19.8%, primarily fueled by large patient populations in China and increasing research collaborations.

Europe, the third-largest market, sees rising adoption of DNA- and RNA-based viral therapies, supported by government initiatives and structured cancer strategies in the UK and other countries.

Segment Analysis
Commercialized Therapies: Imlygic leads the market with a 22% share, followed by RIGVIR and Oncorine. Imlygic provides treatment for unresectable recurrent cancers, while RIGVIR demonstrates significant response rates for melanoma and other cancers.

Pipeline Therapies: Phase I trials dominate with a 35% market share, reflecting ongoing early-stage innovation and increasing clinical translation of research.

Type of Virus: Herpes Simplex Virus (HSV) remains the most prevalent, holding 28% of the market due to its strong genetic adaptability and anti-tumor properties.

Application Insights: Solid tumors, including breast, prostate, lung, glioblastoma, and melanoma, lead the applications segment, with a projected CAGR of 28.6%, emphasizing the therapy’s effectiveness in targeting abnormal tissue masses.

Key Players in the Market
Amgen Inc, DAIICHI SANKYO COMPANY LIMITED, DNAtrix, Genelux, Oncolytics Biotech Inc, PsiOxus Therapeutics, RIGVIR Ltd, Shanghai Sunway Biotech Co. Ltd., SillaJen Inc, Sorrento Therapeutics Inc, Takara Bio Inc, Transgene SA, VCNBiosciences, ViroCure, Viralytics Ltd. (Merck & Co., Inc.)

Recent Developments

• January 2023: AMJEVITA™ (adalimumab-atto) became available in the US as the first Humira® biosimilar, approved by the FDA.

• January 2023: Nammi Therapeutics received the third Amgen Golden Ticket, gaining lab space and access to scientific expertise at BioLabs LA.

Oncolytic virus therapies represent a transformative approach in oncology, merging the precision of gene therapy with innovative viral vectors to tackle cancer more effectively. With increasing investments, strong clinical pipelines, and expanding adoption, this market is poised for exponential growth in the next decade.

About Us:
Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.

Contact Us:
Email: [email protected]
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/